Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

BackgroundHeart failure with preserved ejection fraction (HFpEF) is associated with a high risk of mortality and frequent hospitalization. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have favorable cardiovascular protective effect and could decrease the risk of mortality and hospitalization in...

Full description

Bibliographic Details
Main Authors:	Hufang Zhou, Wenhua Peng, Fuyao Li, Yuelin Wang, Baofu Wang, Yukun Ding, Qian Lin, Ying Zhao, Guozhong Pan, Xian Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	sodium-glucose cotransporter 2 inhibitors heart failure with preserved ejection fraction randomized controlled trials systematic review meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.875327/full

Similar Items

Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
by: Hidekatsu Fukuta, et al.
Published: (2022-10-01)

Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses
by: Runmin Li, et al.
Published: (2023-05-01)

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with a Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials
by: Yake Lou, et al.
Published: (2022-10-01)

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis
by: Sukrit Treewaree, et al.
Published: (2023-02-01)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01)

Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fraction
by: Magdy Abdelhamid, et al.
Published: (2022-04-01)

Effects of different sodium–glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis
by: Xiaohua Lan, et al.
Published: (2024-05-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
by: Resham Raj Poudel
Published: (2013-01-01)

Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool
by: Sanjay Kalra, et al.
Published: (2017-01-01)

Sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis
by: Evgeny M. Mezhonov, et al.
Published: (2023-04-01)

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
by: Jan P. Kleinjan, et al.
Published: (2024-03-01)

Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
by: Yuri Sakai Ishizaki, et al.
Published: (2024-11-01)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022-02-01)

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
by: Boyang Xiang, et al.
Published: (2021-04-01)

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
by: Koki Chiba, et al.
Published: (2021-02-01)

Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study
by: Bin Zhao, et al.
Published: (2021-08-01)

Sodium–glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice
by: Miho Murashima, et al.
Published: (2022-04-01)

Assessment of the Utilization of Sodium–Glucose Cotransporter-2 Inhibitors in Patients Without Diabetes
by: Takuma Koinuma, et al.
Published: (2024-12-01)

Perioperative euglycemic DKA: The YIN and YANG of sodium-glucose cotransporter 2 inhibitors
by: Shilpushp Bhosale, et al.
Published: (2025-01-01)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions
by: Habib Yaribeygi, et al.
Published: (2023-01-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report
by: Megumi Yasuda, et al.
Published: (2020-05-01)

Safety of sodium–glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations
by: Jaime A Davidson, et al.
Published: (2023-02-01)

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials
by: Luxi Ji, et al.
Published: (2023-03-01)

Effect of sodium glucose cotransporter 2 inhibition immediately prior to heart transplantation
by: Lisa M. Raven, MBBS, FRACP, et al.
Published: (2024-08-01)

Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor
by: In-Young Nho, et al.
Published: (2018-12-01)

The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure
by: M. Yu. Kolesnyk, et al.
Published: (2024-03-01)

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
by: Yao Hao Teo, et al.
Published: (2021-03-01)

Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction
by: Kim A. Connelly, et al.
Published: (2018-07-01)

Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
by: Xiaolan Ouyang, et al.
Published: (2023-05-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
by: Mathew John, et al.
Published: (2016-01-01)

Influence of sodium/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis
by: Qian Wang, et al.
Published: (2024-06-01)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
by: He Sun, et al.
Published: (2023-01-01)

Update on Sodium Glucose Cotransporter Type 2 Inhibitors Use in Kidney Transplant Patients
by: Maurizio Salvadori, et al.
Published: (2024-09-01)

Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01)

Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease
by: HUANG Lichenlu, ZHANG Jiarui, ZHENG Yongqin, HE Jundong
Published: (2023-10-01)

Effects of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression: a multi-state survival model
by: Amarit Tansawet, et al.
Published: (2024-11-01)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
by: Fan Yang, et al.
Published: (2020-12-01)